Clinical Report: Comparison of Pharmacokinetic-Based and Weight-Based Coagulation Factor Replacement

Overview

This study compares the perioperative bleeding risk and economic outcomes of pharmacokinetic (PK)-guided versus weight-guided coagulation factor replacement in hemophilia patients undergoing joint arthroplasty.

Background

Hemophilia is a genetic bleeding disorder that increases the risk of bleeding during surgical procedures, particularly joint arthroplasties. Effective coagulation factor replacement therapy is crucial for managing these patients' perioperative risks. Traditional weight-based dosing may not adequately address individual patient needs, prompting the exploration of PK-guided approaches.

Data Highlights

Key Findings

• 33 male patients with a median age of 39 years were included in the study.
• 75.8% of patients had severe hemophilia.
• The PK-guided group had significantly lower hospitalization costs compared to the weight-guided group (p = 0.0073).
• Median coagulation factor consumption was lower in the PK-guided group (701.6 IU/kg) compared to the weight-guided group (892.9 IU/kg, p = 0.0304).
• Median intraoperative blood loss and perioperative hemoglobin decrease were comparable between both groups.

Clinical Implications

The findings indicate differences in cost and factor consumption between PK-guided and weight-guided approaches.

Conclusion

PK-guided coagulation factor infusion regimens may offer different outcomes for hemophilia patients undergoing joint arthroplasty.

Related Resources & Content

1. Impact of Preoperative Anemia and Postoperative Hemoglobin Levels on Hospital Expenses Following Total Knee Arthroplasty, 2023
2. Assessing the Efficacy of Preventive Approaches in Hemophilia A Treatment: A Longitudinal Observational Study in Real-World Settings, 2024
3. Administration of Intravenous Tranexamic Acid During Surgery for Femoral Fragility Fractures Significantly Lowers Blood Transfusion Needs by 75%, 2022
4. WF Treatment Guidelines 3ed_ENG, 2020
5. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial), 2021
6. Archives of Orthopaedic and Trauma Surgery (Springer) — 20 years of blood management and VTE prevention in orthopedic surgery in the Netherlands – a nationwide survey
7. WFH Guidelines for the Management of Hemophilia
8. Perioperative pharmacokinetic-guided factor VIII concentrate dosing in haemophilia (OPTI-CLOT trial): an open-label, multicentre, randomised, controlled trial - PubMed
9. Non-Factor Hemophilia Therapies A Focus of New Recommendations | NBDF